NCT03780361View on ClinicalTrials.gov

Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in DME Patients Treated With Aflibercept (FORESIGHT)

PHASE4CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 17, 2019

Primary Completion Date

January 1, 2023

Study Completion Date

February 1, 2024

Conditions
Diabetic Macular Edema
Interventions
DRUG

Aflibercept Injection

Total 5 times of monthly intravitreal aflibercept injections will be done.

Trial Locations (1)

05030

Konkuk medical center, Seoul

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Hyewon Chung

OTHER

NCT03780361 - Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in DME Patients Treated With Aflibercept (FORESIGHT) | Biotech Hunter | Biotech Hunter